PHLBX: PGIM Jennison Health Sciences B

Welcome to MutualFunds.com. Please help us personalize your experience.

Select the one that best describes you

Your personalized experience is almost ready.

Join other Individual Investors receiving FREE personalized market updates and research. Join other Institutional Investors receiving FREE personalized market updates and research. Join other Financial Advisors receiving FREE personalized market updates and research.

Thank you!

Check your email and confirm your subscription to complete your personalized experience.

Thank you for your submission, we hope you enjoy your experience

Channels

Find the latest content and information here about the 2019 Charles Schwab Impact Conference.

Advisors

Receive email updates about fund flows, news, upcoming CE accredited webcasts from industry thought leaders and more.

Content focused on helping financial advisors build successful client relationships and grow their business.

Content geared towards helping financial advisors build better client portfolios.

Get insights on the industry trends and investment news from leading fund managers and experts.

PHLBX PGIM Jennison Health Sciences B

  • Fund
  • PHLBX
  • Price as of: Jan 16, 2020
  • $31.79
    + $0.21 + 0.67%

Profile

PHLBX - Profile

Vitals

  • YTD Return 2.4%
  • 3 Yr Annualized Return 2.5%
  • 5 Yr Annualized Return -4.9%
  • Net Assets $1.9 B
  • Holdings in Top 10 38.5%

52 WEEK LOW AND HIGH

$31.79
$26.83
$32.38

Expenses

OPERATING RELATED FEES

  • Expense Ratio 1.96%

SALES FEES

  • Front Load N/A
  • Deferred Load 5.00%

BROKERAGE FEES

  • Turnover 36.00%

TRADING FEES

  • Max Redemption Fee N/A

Min Investment

Closed to new investors as of Jun 23, 2014
  • Standard (Taxable) $2,500
  • IRA $1,000

Fund Classification


Distributions

  • YTD Total Return 2.4%
  • 3 Yr Annualized Total Return 2.5%
  • 5 Yr Annualized Total Return -4.9%
  • Capital Gain Distribution Frequency Annually
  • Net Income Ratio -1.46%
DIVIDENDS
  • Dividend Yield 0.0%
  • Dividend Distribution Frequency Annually

Fund Details

  • Legal Name
    PGIM Jennison Health Sciences Fund- Class B
  • Fund Family Name
    PGIM Funds (Prudential)
  • Inception Date
    Jun 30, 1999
  • Shares Outstanding
    N/A
  • Share Class
    B
  • Currency
    USD
  • Domiciled Country
    United States
  • Manager
    David Chan

Fund Description

The fund seeks investments whose prices will increase over time. It normally invests at least 80% of its investable assets in equity and equity-related securities of companies within the health sciences sector, such as pharmaceutical companies, biotechnology companies, medical device manufacturers, healthcare service providers and health maintenance organizations (HMOs) and other companies that derive at least 50% of their assets, revenues or profits from operations in the healthcare sector. The fund is non-diversified.


Get Updates About PHLBX

Sign up for Advisor Access to receive email updates about PHLBX competitors, news, CE accredited webcasts and more.

Please Enter Your Email
Please Select Your Advisor Type

Categories

Performance

PHLBX - Performance

Return Ranking - Trailing

Period PHLBX Return Category Return Low Category Return High Rank in Category (%)
YTD 2.4% 0.0% 6.2% 41.09%
1 Yr 5.1% 2.9% 41.8% 94.96%
3 Yr 2.5%* -9.3% 27.9% 88.07%
5 Yr -4.9%* -9.8% 14.7% 94.23%
10 Yr 5.3%* -2.7% 18.8% 69.32%

* Annualized

Return Ranking - Calendar

Period PHLBX Return Category Return Low Category Return High Rank in Category (%)
2019 11.7% 5.7% 55.4% 89.92%
2018 -19.0% -25.3% 21.5% 91.89%
2017 22.2% -10.8% 43.9% 25.69%
2016 -19.1% -31.6% 6.9% 65.09%
2015 -12.1% -20.4% 13.8% 93.20%

Total Return Ranking - Trailing

Period PHLBX Return Category Return Low Category Return High Rank in Category (%)
YTD 2.4% 0.0% 6.2% 41.09%
1 Yr 5.1% 2.9% 41.8% 94.96%
3 Yr 2.5%* -9.3% 31.1% 90.83%
5 Yr -4.9%* -9.8% 16.6% 95.19%
10 Yr 5.3%* -2.7% 18.8% 85.23%

* Annualized

Total Return Ranking - Calendar

Period PHLBX Return Category Return Low Category Return High Rank in Category (%)
2019 11.7% 5.7% 55.4% 89.92%
2018 -19.0% -25.3% 22.2% 92.79%
2017 22.2% -10.8% 45.8% 34.86%
2016 -19.1% -26.4% 8.7% 78.30%
2015 -12.1% -16.6% 15.2% 95.15%

NAV & Total Return History


Holdings

PHLBX - Holdings

Concentration Analysis

PHLBX Category Low Category High PHLBX % Rank
Net Assets 1.9 B 3.58 M 48.1 B 27.56%
Number of Holdings 72 18 399 63.57%
Net Assets in Top 10 735 M 71.5 K 17.4 B 27.91%
Weighting of Top 10 38.45% 21.3% 75.3% 58.91%

Top 10 Holdings

  1. Sarepta Therapeutics Inc 4.71%
  2. Biomarin Pharmaceutical Inc 4.66%
  3. Sage Therapeutics Inc 4.53%
  4. Illumina Inc 4.20%
  5. Intuitive Surgical Inc 4.17%
  6. UnitedHealth Group Inc 3.62%
  7. DexCom Inc 3.27%
  8. Boston Scientific Corp 3.18%
  9. AstraZeneca PLC ADR 3.08%
  10. Vertex Pharmaceuticals Inc 3.03%

Asset Allocation

Weighting Return Low Return High PHLBX % Rank
Stocks
99.11% 48.12% 103.54% 30.23%
Cash
0.79% 0.00% 51.88% 57.36%
Other
0.10% -27.41% 5.17% 38.76%
Preferred Stocks
0.00% 0.00% 1.08% 42.64%
Convertible Bonds
0.00% 0.00% 1.54% 37.21%
Bonds
0.00% 0.00% 20.60% 34.11%

Stock Sector Breakdown

Weighting Return Low Return High PHLBX % Rank
Healthcare
98.85% 58.44% 100.00% 73.64%
Basic Materials
0.82% 0.00% 2.02% 3.88%
Financial Services
0.33% 0.00% 6.09% 11.63%
Utilities
0.00% 0.00% 0.00% 29.46%
Technology
0.00% 0.00% 16.36% 51.94%
Real Estate
0.00% 0.00% 5.84% 34.88%
Industrials
0.00% 0.00% 2.40% 37.21%
Energy
0.00% 0.00% 0.43% 33.33%
Communication Services
0.00% 0.00% 1.02% 33.33%
Consumer Defense
0.00% 0.00% 36.20% 35.66%
Consumer Cyclical
0.00% 0.00% 10.50% 34.88%

Stock Geographic Breakdown

Weighting Return Low Return High PHLBX % Rank
US
88.96% 48.12% 99.93% 22.48%
Non US
10.15% 0.00% 39.36% 73.64%

Expenses

PHLBX - Expenses

Operational Fees

PHLBX Fees (% of AUM) Category Return Low Category Return High Rank in Category (%)
Expense Ratio 1.96% 0.10% 9.84% 22.83%
Management Fee 0.72% 0.09% 1.30% 53.49%
12b-1 Fee 1.00% 0.00% 1.00% 75.71%
Administrative Fee N/A 0.03% 0.40% N/A

Sales Fees

PHLBX Fees (% of AUM) Category Return Low Category Return High Rank in Category (%)
Front Load N/A 2.50% 5.75% N/A
Deferred Load 5.00% 1.00% 5.00% 4.35%

Trading Fees

PHLBX Fees (% of AUM) Category Return Low Category Return High Rank in Category (%)
Max Redemption Fee N/A 1.00% 2.00% N/A

Related Fees

Turnover provides investors a proxy for the trading fees incurred by mutual fund managers who frequently adjust position allocations. Higher turnover means higher trading fees.

PHLBX Fees (% of AUM) Category Return Low Category Return High Rank in Category (%)
Turnover 36.00% 0.00% 341.00% 47.58%

Distributions

PHLBX - Distributions

Dividend Yield Analysis

PHLBX Category Low Category High PHLBX % Rank
Dividend Yield 0.00% 0.00% 5.21% 37.21%

Dividend Distribution Analysis

PHLBX Category Low Category High Category Mod
Dividend Distribution Frequency Annually Annually Annually Annually

Net Income Ratio Analysis

PHLBX Category Low Category High PHLBX % Rank
Net Income Ratio -1.46% -2.24% 2.12% 97.64%

Capital Gain Distribution Analysis

PHLBX Category Low Category High Capital Mode
Capital Gain Distribution Frequency Annually Annually Annually Annually

Dividend Payout History

View More +

Fund Manager Analysis

PHLBX - Fund Manager Analysis

Managers

David Chan


Start Date

Tenure

Tenure Rank

Jun 30, 1999

20.52

20.5%

David Chan, CFA, is a Managing Director and a Health Sciences Equity Portfolio Manager and Research Analyst of Jennison. Mr. Chan joined Jennison Associates in May 1992. He was previously with the Boston Consulting Group, where he was a team leader and consultant on projects in a wide variety of industries, but with a special focus in the health care area. Mr. Chan has also worked in various positions in the film and television industry. He received a BA in biochemistry from Harvard University and an MBA from Columbia University.

Debra Netschert


Start Date

Tenure

Tenure Rank

Jan 28, 2015

4.93

4.9%

Debra Netschert is a Managing Director and a Health Sciences Equity Portfolio Manager and Research Analyst of Jennison. Ms. Netschert joined Jennison Associates in January 2008. Prior to Jennison, Ms. Netschert worked at Magnetar Capital where she was a senior analyst responsible for health care coverage with an emphasis on biotechnology and pharmaceutical industries. Prior to her experience at Magnetar Capital, Ms. Netschert worked at Amaranth Advisors as a biotechnology analyst. From 2002 to 2004, she was vice president and senior analyst for biotechnology at Lazard Capital Markets. Ms. Netschert began her research career as an associate biotechnology analyst at UBS in 2000. She received her BS and MS from Boston University.

Tenure Analysis

Category Low Category High Category Average Category Mode
0.59 22.31 9.83 19.68